Sculptor Capital’s Inovio Pharmaceuticals INO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q1
Sell
-59,475
Closed -$3.56M 1266
2021
Q4
$3.56M Hold
59,475
0.03% 467
2021
Q3
$5.11M Hold
59,475
0.04% 323
2021
Q2
$6.62M Buy
59,475
+33,900
+133% +$3.26M 0.05% 253
2021
Q1
$2.85M Buy
25,575
+12,742
+99% +$1.68M 0.02% 377
2020
Q4
$1.36M Sell
12,833
-7,142
-36% -$951K 0.01% 322
2020
Q3
$2.78M Sell
19,975
-5,717
-22% -$1.19M 0.02% 217
2020
Q2
$8.31M Buy
25,692
+4,775
+23% +$767K 0.07% 107
2020
Q1
$1.87M Buy
+20,917
New +$1.29M 0.03% 136

Other funds holding INO

Sculptor Capital's INO Position: Q1 2022 in Review

Sculptor Capital sold out of Inovio Pharmaceuticals (INO) in Q1 2022, closing a stake of 59,475 shares — an estimated $3.56M sold.

Sculptor Capital first reported a position in INO in Q1 2020 and held it in 8 quarters. The position peaked at $8.31M in Q2 2020. 198 funds tracked by Wall St. Rank hold INO as of Q1 2022.

  • Sculptor Capital reported no remaining Inovio Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Sculptor Capital sold 59,475 Inovio Pharmaceuticals shares in Q1 2022, an estimated $3.56M.
  • Sculptor Capital first reported a position in Inovio Pharmaceuticals in Q1 2020 and held it in 8 quarters.
  • Sculptor Capital's Inovio Pharmaceuticals position peaked at $8.31M in Q2 2020.
  • 198 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2022.

Based on Sculptor Capital's 13F filing for Q1 2022, filed 13 May 2022.